Predict your next investment

Corporation
HEALTHCARE | Pharmaceuticals / Drugs
takeda.com

See what CB Insights has to offer

Investments

25

Portfolio Exits

9

Partners & Customers

10

Service Providers

1

About Takeda Pharmaceutical

Takeda Pharmaceutical (TYO: 4502) (NYSE: TAK) is a research-based, global pharmaceutical company. Takeda is committed to striving toward better health for patients worldwide through innovation in medicine.

Takeda Pharmaceutical Headquarter Location

2-1-1 Nihonbashihonmachi, Chuo-ku

Tokyo, 103-8668,

Japan

+81 (0)3 3278 2111

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Takeda Pharmaceutical

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Takeda Pharmaceutical in 3 Expert Collections, including Poop Tech.

P

Poop Tech

114 items

P

Pharma Startups

5,090 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

R

Rare Diseases

25 items

Takeda Pharmaceutical Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Takeda Pharmaceutical Rank

Research containing Takeda Pharmaceutical

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Takeda Pharmaceutical in 2 CB Insights research briefs, most recently on Apr 19, 2021.

Latest Takeda Pharmaceutical News

Immusoft, Takeda in potential $900M+ rare metabolic disease deal

Oct 14, 2021

Oct. 13, 2021 In its first big pharma deal since it was founded around a cell programming technology in 2009, Immusoft Corp. signed Takeda Pharmaceutical Co. Ltd. to a research collaboration and license option targeting rare inherited metabolic disorders. The agreement brings an undisclosed up-front fee and research funding to Immusoft, which is also eligible to earn more than $900 million if all options are exercised and all milestones hit.

Takeda Pharmaceutical Investments

25 Investments

Takeda Pharmaceutical has made 25 investments. Their latest investment was in Adaptate Biotherapeutics as part of their Series A on April 4, 2021.

CBI Logo

Takeda Pharmaceutical Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

4/20/2021

Series A

Adaptate Biotherapeutics

$18M

Yes

2

4/1/2021

Seed VC

Orizuru Therapeutics

$9.07M

Yes

4

10/6/2020

Seed VC

xFOREST Therapeutics

Yes

2

6/25/2020

Series E

Subscribe to see more

$99M

Subscribe to see more

10

5/20/2020

Series C - IV

Subscribe to see more

$99M

Subscribe to see more

10

Date

4/20/2021

4/1/2021

10/6/2020

6/25/2020

5/20/2020

Round

Series A

Seed VC

Seed VC

Series E

Series C - IV

Company

Adaptate Biotherapeutics

Orizuru Therapeutics

xFOREST Therapeutics

Subscribe to see more

Subscribe to see more

Amount

$18M

$9.07M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

4

2

10

10

Takeda Pharmaceutical Portfolio Exits

9 Portfolio Exits

Takeda Pharmaceutical has 9 portfolio exits. Their latest portfolio exit was AmWell on September 17, 2020.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

9/17/2020

IPO

$991

11

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

Date

9/17/2020

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Exit

IPO

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

$991

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

11

10

10

10

10

Takeda Pharmaceutical Acquisitions

22 Acquisitions

Takeda Pharmaceutical acquired 22 companies. Their latest acquisition was HilleVax on July 31, 2021.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

7/31/2021

Spinoff / Spinout

$135M

Spinoff / Spinout

1

3/9/2021

Partnership

$991

$56M

Acquired

9

4/16/2020

Acquired

1

2/26/2020

Corporate Minority

Subscribe to see more

$991

$99M

Subscribe to see more

10

4/25/2018

Subscribe to see more

$991

$99M

Subscribe to see more

10

Date

7/31/2021

3/9/2021

4/16/2020

2/26/2020

4/25/2018

Investment Stage

Spinoff / Spinout

Partnership

Corporate Minority

Companies

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

$991

Total Funding

$135M

$56M

$99M

$99M

Note

Spinoff / Spinout

Acquired

Acquired

Subscribe to see more

Subscribe to see more

Sources

1

9

1

10

10

Takeda Pharmaceutical Partners & Customers

10 Partners and customers

Takeda Pharmaceutical has 10 strategic partners and customers. Takeda Pharmaceutical recently partnered with World Food Programme on September 9, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

9/22/2021

Partner

World Food Programme

Italy

WFP and Takeda deepen partnership in West Africa to strengthen health emergency response

WFP and Takeda Pharmaceutical Company Limited deepen partnership in West Africa to strengthen health emergency response .

1

9/8/2021

Licensor

Novavax

United States

Takeda to deliver Novavax’s Covid-19 vaccine doses to Japan

In August last year , Takeda Pharmaceutical entered a partnership with Novavax to develop , produce and market the latter 's covid‑19 vaccine candidate in Japan .

1

8/23/2021

Licensor

Genevant

United States

Genevant Sciences Announces Global Collaboration and License Agreement with Takeda to Develop Novel Nonviral Gene Therapies for Up to Two Rare Liver Diseases

This is the second collaboration between Genevant Sciences Corporation and Takeda Pharmaceutical Company Limited , following an earlier 2021 agreement to develop nucleic acid therapeutics directed to specified targets in hepatic stellate cells to treat liver fibrosis .

4

8/10/2021

Licensor

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

7/30/2021

Licensee

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

9/22/2021

9/8/2021

8/23/2021

8/10/2021

7/30/2021

Type

Partner

Licensor

Licensor

Licensor

Licensee

Business Partner

World Food Programme

Novavax

Genevant

Country

Italy

United States

United States

Subscribe to see more

Subscribe to see more

News Snippet

WFP and Takeda deepen partnership in West Africa to strengthen health emergency response

WFP and Takeda Pharmaceutical Company Limited deepen partnership in West Africa to strengthen health emergency response .

Takeda to deliver Novavax’s Covid-19 vaccine doses to Japan

In August last year , Takeda Pharmaceutical entered a partnership with Novavax to develop , produce and market the latter 's covid‑19 vaccine candidate in Japan .

Genevant Sciences Announces Global Collaboration and License Agreement with Takeda to Develop Novel Nonviral Gene Therapies for Up to Two Rare Liver Diseases

This is the second collaboration between Genevant Sciences Corporation and Takeda Pharmaceutical Company Limited , following an earlier 2021 agreement to develop nucleic acid therapeutics directed to specified targets in hepatic stellate cells to treat liver fibrosis .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

1

4

10

10

Takeda Pharmaceutical Service Providers

1 Service Provider

Takeda Pharmaceutical has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Acq - P2P

Investment Bank

Financial Advisor

Service Provider

Associated Rounds

Acq - P2P

Provider Type

Investment Bank

Service Type

Financial Advisor

Partnership data by VentureSource

Takeda Pharmaceutical Team

20 Team Members

Takeda Pharmaceutical has 20 team members, including current Chief Executive Officer, President, Yasuchika Hasegawa.

Name

Work History

Title

Status

Yasuchika Hasegawa

Chief Executive Officer, President

Current

Frank Morich

Chief Executive Officer

Current

Jeremy G Chadwick

Senior Vice President

Current

Daniel Curran

Senior Vice President

Current

Thom K.

dRx Capital, Cambia Health Solutions, Northwestern Medicine, and Adams Street Partners

Investment Partner

Current

Name

Yasuchika Hasegawa

Frank Morich

Jeremy G Chadwick

Daniel Curran

Thom K.

Work History

dRx Capital, Cambia Health Solutions, Northwestern Medicine, and Adams Street Partners

Title

Chief Executive Officer, President

Chief Executive Officer

Senior Vice President

Senior Vice President

Investment Partner

Status

Current

Current

Current

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.